Zachary E Stiles1, Paxton V Dickson1, Evan S Glazer1, Andrew J Murphy2,3, Andrew M Davidoff2,3, Stephen W Behrman1, Michael W Bishop4, Michael G Martin5, Jeremiah L Deneve1. 1. Division of Surgical Oncology, Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee. 2. Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Division of Pediatric Surgery, Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee. 4. Division of Solid Tumor, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 5. Department of Hematology and Oncology, West Cancer Center, Memphis, Tennessee.
Abstract
BACKGROUND AND OBJECTIVES: Desmoplastic small round cell tumor (DSRCT) is a rare peritoneal surface malignancy. Current research is limited by the scarcity of this disease. METHODS: Patients with DSRCT were identified in the 2004-2014 NCDB. Factors affecting overall survival (OS) were assessed. Additionally, trends were examined based on the volume of cases treated at individual facilities. RESULTS: A total of 125 patients were identified with a median age of 21 (IQR 15-27). Six had extra-abdominal disease and 15 (12%) had liver involvement. Median OS was 28 months. Systemic chemotherapy (HR 0.4, P = 0.015) and surgery (HR 0.6, P = 0.047) were associated with reduced mortality. For the 74 patients undergoing surgery, absence of liver involvement and receipt of postoperative chemotherapy were associated with improved OS on univariate analysis. On multivariable analysis, two factors approached significance: adjuvant chemotherapy was associated with a reduced risk of mortality (HR 0.3, P = 0.073) and residual macroscopic disease after resection correlated with increased risk of mortality (HR 5.3, P = 0.071). High-volume facilities (≥5 cases) experienced improved OS (median 59.1 vs 28.8 months), albeit not significantly (P = 0.135), compared to low-volume centers. CONCLUSION: Despite multimodal treatment, DSRCT is associated with dismal outcomes. Facilities familiar with treating this uncommon disease may experience superior outcomes.
BACKGROUND AND OBJECTIVES:Desmoplastic small round cell tumor (DSRCT) is a rare peritoneal surface malignancy. Current research is limited by the scarcity of this disease. METHODS:Patients with DSRCT were identified in the 2004-2014 NCDB. Factors affecting overall survival (OS) were assessed. Additionally, trends were examined based on the volume of cases treated at individual facilities. RESULTS: A total of 125 patients were identified with a median age of 21 (IQR 15-27). Six had extra-abdominal disease and 15 (12%) had liver involvement. Median OS was 28 months. Systemic chemotherapy (HR 0.4, P = 0.015) and surgery (HR 0.6, P = 0.047) were associated with reduced mortality. For the 74 patients undergoing surgery, absence of liver involvement and receipt of postoperative chemotherapy were associated with improved OS on univariate analysis. On multivariable analysis, two factors approached significance: adjuvant chemotherapy was associated with a reduced risk of mortality (HR 0.3, P = 0.073) and residual macroscopic disease after resection correlated with increased risk of mortality (HR 5.3, P = 0.071). High-volume facilities (≥5 cases) experienced improved OS (median 59.1 vs 28.8 months), albeit not significantly (P = 0.135), compared to low-volume centers. CONCLUSION: Despite multimodal treatment, DSRCT is associated with dismal outcomes. Facilities familiar with treating this uncommon disease may experience superior outcomes.
Authors: Zachary E Stiles; Andrew J Murphy; Doralina L Anghelescu; Christina-Lin Brown; Andrew M Davidoff; Paxton V Dickson; Evan S Glazer; Michael W Bishop; Wayne L Furman; Alberto S Pappo; John T Lucas; Jeremiah L Deneve Journal: Ann Surg Oncol Date: 2019-04-08 Impact factor: 5.344
Authors: Monika Scheer; Christian Vokuhl; Bernd Blank; Erika Hallmen; Thekla von Kalle; Marc Münter; Rüdiger Wessalowski; Maite Hartwig; Monika Sparber-Sauer; Paul-Gerhardt Schlegel; Christof M Kramm; Udo Kontny; Bernd Spriewald; Thomas Kegel; Sebastian Bauer; Bernarda Kazanowska; Felix Niggli; Ruth Ladenstein; Gustaf Ljungman; Kirsi Jahnukainen; Jörg Fuchs; Stefan S Bielack; Thomas Klingebiel; Ewa Koscielniak Journal: Cancer Med Date: 2019-01-16 Impact factor: 4.452
Authors: Celso Abdon Mello; Fernando Augusto Batista Campos; Tiago Goss Santos; Maria Leticia Gobo Silva; Giovana Tardin Torrezan; Felipe D'Almeida Costa; Maria Nirvana Formiga; Ulisses Nicolau; Antonio Geraldo Nascimento; Cassia Silva; Maria Paula Curado; Suely Akiko Nakagawa; Ademar Lopes; Samuel Aguiar Journal: Cancers (Basel) Date: 2021-01-28 Impact factor: 6.639
Authors: Fernando Campos; Daniel L Coutinho; Maria Letícia G Silva; Ademar Lopes; Antônio Nascimento; Samuel Aguiar Júnior; Ulisses R Nicolau; Maria Nirvana Formiga; Felipe D'Almeida Costa; Celso Mello Journal: Sarcoma Date: 2020-10-28